Who are CYCLOSPORINE VS INFLIXIMAB's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyclosporine-vs-infliximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CYCLOSPORINE VS INFLIXIMAB — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CYCLOSPORINE VS INFLIXIMAB (CYCLOSPORINE VS INFLIXIMAB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab). Area: Immunology / Gastroenterology.

marketed Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab) Calcineurin (cyclosporine); TNF-alpha (infliximab) Immunology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

CYCLOSPORINE VS INFLIXIMAB (CYCLOSPORINE VS INFLIXIMAB) — Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. This is a comparative study evaluating cyclosporine (a calcineurin inhibitor) versus infliximab (a TNF-alpha inhibitor) for inflammatory bowel disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CYCLOSPORINE VS INFLIXIMAB TARGET	CYCLOSPORINE VS INFLIXIMAB	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab)	Calcineurin (cyclosporine); TNF-alpha (infliximab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab) class)

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CYCLOSPORINE VS INFLIXIMAB — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclosporine-vs-infliximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab